Articles
Read our latest news and updates.
For media inquiries, contact us at media@compasspathways.com
-
April 27, 2020
Compass Pathways concludes successful Series B investment round
Read article
-
April 22, 2020
Looking after our world, one tree at a time
Read article
-
April 07, 2020
The experts behind our clinical trial
Read article
-
March 25, 2020
Protecting our communities and our teams during the COVID-19 pandemic
Read article
-
March 08, 2020
Inspiring our next generation of women
Read article
-
January 15, 2020
Compass Pathways granted patent covering use of its psilocybin formulation in addressing treatment-r...
Read article
-
January 08, 2020
Should psilocybin be legalised?
Read article
-
January 08, 2020
Why do we seek patent protection?
Read article
-
January 08, 2020
How will we make psilocybin therapy accessible to all who need it, not just those who can afford it?
Read article
-
January 08, 2020
What is our policy on Open Science and how do we work with independent researchers?
Read article
-
January 07, 2020
How do we train our therapists and do we require them to have personal experience with psilocybin?
Read article
-
January 03, 2020
Compass Pathways News | December 2019 Issue
Read article
-
December 19, 2019
George and Ekaterina at the CNS Summit 2019
Read article
-
December 12, 2019
Compass Pathways and King’s College London announce results from psilocybin study in healthy volun...
Read article
-
July 23, 2019
Compass Pathways News | July 2019 Issue
Read article
-
December 19, 2018
Compass Pathways News | December 2018 Issue
Read article
-
November 11, 2018
Navigating mental health: Compass Pathways’ psilocybin research programme
Read article
-
October 23, 2018
Compass Pathways receives FDA Breakthrough Therapy designation for psilocybin therapy for treatment-...
Read article
-
July 17, 2018
Compass Pathways News | July 2018 Issue
Read article
-
December 19, 2017
Compass Pathways News | December 2017 Issue
Read article